Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study

Mustafa Karaagac,1 Mehmet Artac,1 Sema Sezgin Goksu,2 Melek Karakurt Eryilmaz,1 Hasan Senol Coskun,2 Hakan Bozcuk2

1Department of Medical Oncology, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey
2Department of Medical Oncology, Akdeniz University, Faculty of Medicine, Antalya, Turkey

Abstract

Objectives: Recurrent and progressive small cell lung cancer (SCLC) has a very poor prognosis, and treatment options are limited. Combination of irinotecan with ifosfamide (I-I regimen) in SCLC has limited preliminary data. In this study, we aimed to evaluate the efficacy and toxicity of I-I regimen in patients with previously treated SCLC.

Methods: A total of 25 patients were retrospectively reviewed. Ifosfamide dose was 1500 mg/m² per day, days 1-3, irinotecan 80 mg/m² per day days 1, 8 and 15 every four weeks.

Results: Median age of patients was 55 years (range 42-80). Median chemotherapy cycles were 3 (range 1-7). The frequency of the second, third and fourth line treatments were 68%, 24%, and 8% respectively. Partial remission was obtained in 15 patients (60%) and complete remission in one patient (4%). Median progression free survival (PFS) and overall survival (OS) figures were 7.8 and 11.1 months, respectively. Granulocyte colony stimulating factor (G-CSF) was used in 40% of patients. Grade 3-4 anemia, leukopenia, and thrombocytopenia were seen in 20%, 36% and 12% of these cases, respectively.

Conclusion: Ifosfamide and irinotecan combination is an effective and a tolerable treatment option for patients with platinum refractory SCLC.

Keywords: Chemotherapy, ifosfamide, irinotecan, small cell lung cancer, survival

Cite This Article: Karaagac M, Artac M, Goksu SS, Karakurt Eryilmaz M, Coskun HS, Bozcuk H. Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study. EJMO 2020;4(2):172–176.
can be used as an active chemotherapeutic agent. The use of irinotecan in the treatment of patients with SCLC has also been studied in various studies. A combination of irinotecan and ifosfamide (I-I regimen) has been used successfully in Japan for refractory or progressive SCLC.

We aimed to confirm the feasibility and toxicity of the I-I regimen in our cohort of Turkish patients with platinum-refractory SCLC. This paper is a retrospective report of the real-life data of our patients and the first study to demonstrate the results of the I-I regimen in patients outside of Japan.

Methods

This was a retrospective crossover study. In this study, 25 patients who underwent the I-I regimen at the outpatient chemotherapy units of participating centers between January 2004 and December 2014 were examined. Medical oncologists analyzed all data in the files of the eligible patients.

Patient Selection, Evaluation, and Treatment Details

All patients had histologically or cytologically proven SCLC and were older than 18 years, with an Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤2. All of them had a recurrence or progressive disease that was defined by the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) criteria after at least one line of chemotherapy and then received the treatment protocol. According to the institutional practice guidelines, first-line chemotherapy was always cisplatin and etoposide in the study cohort.

In the treatment protocol, ifosfamide dose was 1500 mg/m²/day with 1500 mg/m²/day mesna coverage, days 1-3, irinotecan 80 mg/m² per day days 1, 8 and 15 every four weeks. Granulocyte-colony stimulating factor (G-CSF) was administered along with the decision of the treating physician. The response evaluation of the patients was done according to RECIST version 1.1. Patients who achieved a complete response (CR), partial response (PR), and stable disease (SD) in accordance with RECIST were defined as responders. In contrast, patients with progressive disease (PD) were identified as non-responders. The overall response rate (ORR) was defined as the responders, including only CR or PR. The laboratory and clinical adverse effects of treatment were calculated using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.

Statistical Analysis

Primary statistical analysis included descriptive statistics of the patients’ characteristics (gender, age, performance status, the line of treatment).

Progression-free survival (PFS) was calculated as the time from the beginning of treatment to the date of first disease progression or death. Overall survival (OS) was determined by measuring the time from diagnosis to death. All patients underwent PFS and OS analysis.

Statistical analysis was performed by using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics were calculated as proportions and medians. The Kaplan–Meier method was used for survival analysis. The median PFS and OS were calculated, and survival curves were constructed. A p-value of less than 0.05 was required for statistical significance.

Results

Patient Characteristics

The median age was 55 years (range 42-80), and the majority of patients (96%) were male. The number of treatment cycles for patients ranged from 1-7. Median chemotherapy cycles were 3. The second-line treatment was the most common setting that the I-I regimen was used, and the frequency of the second, third, and fourth-line treatments was 68%, 24%, and 8%, respectively. Please refer to Table 1 for details.

Efficacy and Toxicity of Treatment

The PR was obtained in 15 patients (60%), and CR was obtained in one patient (4%). When pooled with the Ichiki series, the resultant response rate becomes 57.6% and the complete response rate of 5.1%. Details are given in Table 2. The median PFS and OS figures were 7.8 and 11.1 months, respectively. See Figures 1 and 2 for the survival curves. G-CSF was used in 40% of patients. The toxicity was generally manageable, and grade 3-4 anemia, leukemia, and thrombocytopenia were seen in 20%, 36%, and 12% of these

Table 1. Patient and Treatment Characteristics

|                          | n (%) | Median | Minimum | Maximum |
|---------------------------|-------|--------|---------|---------|
| All patients              | 25 (100) |        |         |         |
| Age                       | 55    | 42     | 80      |         |
| Gender Male               | 24 (96) |        |         |         |
| Total cycles of I-I regimen* received | 3 | 1 | 7 | |
| The line of I-I regimen*  |       |        |         |         |
| 2nd line                  | 17 (68) |        |         |         |
| 3rd line                  | 6 (24)  |        |         |         |
| 4th line                  | 2 (8)   |        |         |         |

*: Combination of irinotecan and ifosfamide.
cases, respectively. No dose reduction was required in any patient. Treatment-related mortality did not occur.

**Discussion**

This was a unique study that included real-life data of I-I regimen from patients outside East Asia. Although the number of patients in our cohort was small, we observed that ifosfamide and irinotecan combination in SCLC was effective and tolerable after progression with cisplatin-based chemotherapy. Toxicity was manageable and acceptable. Treatment efficacy was not associated with the standard prognostic factors. In this regard, we conclude that this protocol is worth exploring further, as ifosfamide and irinotecan are two agents with the highest individual response rate in the refractory setting and, also, it has also been shown that nonplatinum combinations do not yield inferior survival in the management of SCLC when compared to platinum agents. [19] Proper clinical trials are needed to test this regimen in the refractory metastatic SCLC.

The median OS figure of 11 months achieved with this combination in refractory patients with SCLC in this study was among the highest reported so far in this setting. For example, topotecan used parenterally achieved a median overall survival of 25 weeks (i.e., around six months), and is the only approved agent in this setting. In parallel, the combination of cyclophosphamide, doxorubicin, and vincristine (CAV) again yielded a median overall survival of 24.7 weeks, around six months, as well. [2,20] Also, when our response data was pooled with the series of Ichiki, a response rate of 57% was achieved, and this rate compared very favorably with that of topotecan (24.3%) and CAV (18.3%) or oral topotecan (7%). [21] On the other hand, response rates with combination chemotherapy in the relapsed setting were higher than those by single agents and varied between 17% with single agents and 88% with combinations. [22,23]

Ifosfamide was used mainly with etoposide and a platinum agent in the management of chemo naive patients rather than chemorefractory patients with SCLC, and results showed that ifosfamide combinations were active but more toxic than the etoposide and platinum combination. [10,24] Therefore, it makes sense to use ifosfamide in the refractory SCCL setting in a combination, as is the case with irinotecan-ifosfamide, but without platinum, to maintain efficacy and to limit toxicity.

Myelotoxicity of this protocol was appeared to be manageable, although 40% of cases used myeloid growth factors. Grade 3-4 neutropenia of 36% with this protocol was not higher than the toxicity caused by topotecan (54%). Thus, the I-I regimen is a potent combination with manageable toxicity.

**Table 2. Pooled results for tumor response with I-I regimen* in progressive SCLC**

|                  | n  | CR (%) | PR (%) | RR (%) |
|------------------|----|--------|--------|--------|
| Ichiki, et al. (2003) | 34 | 2 (5.9) | 16 (47.1) | 18 (52.9) |
| This paper, Karaagac, et al. (2019) | 25 | 1 (4) | 15 (60) | 16 (64) |
| Pooled results   | 59 | 3 (5.1) | 31 (52.5) | 34 (57.6) |

Ichiki, et al (2003) data corresponds to reference no 15. *: Combination of irinotecan and ifosfamide; **: Small cell lung cancer.

**Figure 1.** Progression free survival with irinotecan-ifosfamide small cell cancer. Median progression free survival is 7.8 months.

**Figure 2.** Overall survival with irinotecan-ifosfamide small cell cancer. Median overall survival is 11.1 months.
Up to now, no notable success was achieved with the use of biological treatments in refractory SCLC. For example, sunitinib, pazopanib and alisertib yielded response rates of only 8.7%, 0% and 15%, respectively.\[25-27\] Although significant improvements were achieved in the treatment of NSCLC with targeted molecular therapies such as erlotinib and crizotinib, this success has not been possible for SCLC.\[28\] Although many immunotherapy studies focused on NSCLC treatment and significant positive results were obtained, relatively few studies examined the effectiveness of immunotherapy for SCLC treatment, and the results were discouraging.\[29\] In addition to the limited developments in immunotherapy for SCLC treatment, and the results were disappointing.

**Conclusion**

Better therapeutics or more effective combinations are urgently awaited for patients with refractory SCLC. This combination of irinotecan and ifosfamide may be a step to improve treatment results for this group of patients, especially when treatment toxicity and treatment response is a priority. We conclude that the I-I regimen may substitute for topotecan or CAV regimens. Prospective clinical trials are urgently needed to test the utility of this combination further.

**Disclosures**

**Acknowledgment:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. All authors contributed significantly to the study from beginning to the end by making important addititives to conception, design, collection of data, or analysis and interpretation of data, drafting the manuscript or revising it critically.

**Ethics Committee Approval:** The study was performed according to the Declaration of Helsinki and approved by the Local Ethics Committee (Ethics Committee approval number: 2019/2167). Patient informed consent was not required because this was a retrospective cross-sectional file scanning study.

**Peer-review:** Externally peer-reviewed.

**Conflict of Interest:** None declared.

**Authorship Contributions:** Concept – M.K., M.A., H.B.; Design – M.K., M.A., H.B.; Supervision – M.K., H.B.; Materials – M.K., S.S.G, M.K.E, H.S.C., H.B.; Data collection &/or processing – M.K., S.S.G, M.K.E, H.S.C., H.B.; Analysis and/or interpretation – M.K., M.A., H.B.; Literature search – M.K., H.B.; Writing – M.K., M.A., H.B.; Critical review – M.K., M.A., H.B.

**References**

1. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer 2008;113:5–21. [CrossRef]
2. Asai N, Ohkuni Y, Kaneko N, Yamaguchi E, Kubo A. Relapsed small cell lung cancer: treatment options and latest developments. Ther Adv Med Oncol 2014;6:69–82. [CrossRef]
3. Paccagnella A, Favaretto A, Brandes A, Ghiotto C, Fornasiero A, Volpi A, Pappagallo G, et al. Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. Cancer 1990;65:2631–4. [CrossRef]
4. Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 1991;42:428–67. [CrossRef]
5. Kosmidis P, Mylonakis N, Fountzilas G, Pavlidis N, Samantas E, Karabelis A, et al. A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group. Ann Oncol 1996;7:517–20. [CrossRef]
6. Graziano SL, Valone FH, Herndon JE 2nd, Crawford J, Richards F 2nd, Rege VB, Clamon G, Green MR. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 1996;14:315–29. [CrossRef]
7. Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, et al. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 1998;16:1388–96. [CrossRef]
8. Jacot W, Pujol JL, Chakra M, Molinier O, Bozonnat MC, Gervais R, et al. Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients. Lung Cancer 2012;75:213–6. [CrossRef]
9. Boni C, Pagano M, Baldi L, Gnoni R, Braigia L, Savoldi L, et al. Pei regimen: a therapeutic option in small cell lung cancer? A retrospective monoinstitutional analysis of 46 consecutive cases. J Transl Med 2015;13:130. [CrossRef]
10. Lee HS, Lee YG, Koo DH, Oh S, Nam H, Song JU, et al. Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer. Cancer Chemother Pharmacol 2015;76:933–7. [CrossRef]
11. Tanaka I, Kawada K, Morise M, Hase T, Hayashi H, Sokai A, et al. A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting. Cancer Chemother Pharmacol 2018;81:339–345. [CrossRef]
12. Jiang J, Liang X, Zhou X, Huang L, Huang R, Chu Z, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010;5:867–73. [CrossRef]
13. Xu F, Ren X, Chen Y, Li Q, Li R, Chen Y, et al. Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis. BMC Cancer 2018;18:808. [CrossRef]

14. Liu ZL, Wang B, Liu JZ, Liu WW. Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis. J Cancer Res Ther 2018;14(Supplement):S1076–S1083.

15. Ichiki M, Gohara R, Rikimaru T, Kitajima T, Fujiki R, Shimada A, et al. Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study. Chemotherapy 2003;49:200–5. [CrossRef]

16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16. [CrossRef]

17. National Cancer Institute. Common Terminology Criteria for Adverse Events v.4.0 (CTCAE). Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.

18. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn 1958;53:457–81.

19. Amarasena IU, Chatterjee S, Walters JA, Wood-Baker R, Fong KM. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev 2015;CD006849. [CrossRef]

20. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658–67. [CrossRef]

21. O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucević B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441–7.

22. Schuette W, Nagel S, Juergens S, Bork I, Wollschaalger B, Schaedlich S, et al. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer. Clin Lung Cancer 2005;7:133–7. [CrossRef]

23. Kubota K, Nishiwaki Y, Kakinuma R, Hojo F, Matsumoto T, Ohmatsu H, et al. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 1997;15:292–6. [CrossRef]

24. Yang H, Ma Y, Liu Z, Wang Z, Han B, Ma L. Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis. Mol Clin Oncol 2015;3:420–424. [CrossRef]

25. Han JY, Kim HY, Lim KY, Han JH, Lee YJ, Kwak MH, et al. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer 2013;79:137–42. [CrossRef]

26. Gandhi L, Heist RS, Lucca JV, Temel JS, Fidias P, Morse LK, et al. A phase II trial of pazopanib in relapsed/refractory small cell lung cancer (SCLC). 2012 ASCO Annual Meeting. J Clin Oncol 2012;30(Suppl.): abstract 7099. [CrossRef]

27. Lee P, Alvarez RH, Melichar B, Adenis A, Bennouna J, Schusterbauer C, et al. Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: preliminary phase II results. 2012 ASCO Annual Meeting. J Clin Oncol 2012;30(Suppl.): abstract 3010. [CrossRef]

28. Arcaro A. Targeted therapies for small cell lung cancer: Where do we stand? Crit Rev Oncol Hematol 2015;95:154–64. [CrossRef]

29. Li Q, Yuan D, Ma C, Liu Y, Ma L, Lv T, et al. A new hope: the immuno-therapy in small cell lung cancer. Neoplasma 2016;63:342–50.